Skip to main content
US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
EL

ELTXStock

Nasdaq Capital Market · Healthcare · US

$1.44 last close 2026-11-17
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment ELTX's does — no target price to set, unlike a price alert.

Stable Ratio screen, 0 of 7 decided standards passing. No standard's deciding ratio sits within 3 points of its line. What would change it

Sharia status
NOT COMPLIANT
Per our in-house ratio engine
0 of 7 pass our own screen — all 7 agree here
Purification 100.00% *
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No trade setup shown — a stock that isn't cleanly Sharia-compliant never gets a bullish verdict here.

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure0 of 5 timeframes bullish · 65.2% aligned
VWAPPrice below VWAP ($1.52)
VolumeRelative volume 4.4× the 20-day average
Momentum10-day rate of change -5.6%

ELTX is currently considered not halal (non-compliant), per our in-house ratio engine. See the full ratio breakdown and business-activity screen below for the reasoning.

⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.

436 other Healthcare stocks pass this same screen. See compliant Healthcare stocks →

Market & analysts
Price target
$13.00
+805.9% · 3 analysts
Institutional own.
26.3%
of shares
Momentum (10d)
-5.6%
rate of change
SMC grade
F · 24
65.2% aligned
100.00% *
Purification ratio (secondary provider, uncertain)
F · 24
SMC grade — 65.2% timeframe alignment
-5.6%
Rate of change (10d)
$13.00
Price target (+805.9%) · 3 analysts
26.3%
Institutional ownership

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $41.9M as of 2026-11-17.

Business activity: cleared (no excluded categories detected)

AAOIFI Fail 0 of 2 ratios pass
RatioValueThresholdResult
Interest-bearing debt 33.40% 30.00% Fail(3.4pp over)
Interest-bearing investments 74.99% 30.00% Fail(45.0pp over)
Usmani Fail 1 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 35.33% 33.00% Fail(2.3pp over)
Interest-bearing investments 79.34% 33.00% Fail(46.3pp over)
Non-liquid assets 20.66% at least 20.00% Pass(0.7pp above the floor)
MSCI Fail 0 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 35.33% 33.33% Fail(2.0pp over)
Cash + interest-bearing securities 79.34% 33.33% Fail(46.0pp over)
Accounts receivable 79.34% 33.33% Fail(46.0pp over)
FTSE Fail 1 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 24.33% 33.33% Pass(9.0pp buffer)
Cash + interest-bearing securities 79.34% 33.33% Fail(46.0pp over)
Accounts receivable 79.34% 50.00% Fail(29.3pp over)
Dow Jones Islamic Market Fail from an earlier screen 3 of 3 ratios pass

This Fail was decided by an earlier screen. The figures below are from the latest filing, which could not decide it on its own: non-permissible income not measured. The earlier verdict stands until a screen can decide it.

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 8.50% 33.00% Pass(24.5pp buffer)
Cash + interest-bearing securities 19.10% 33.00% Pass(13.9pp buffer)
Accounts receivable 0.00% 33.00% Pass(33.0pp buffer)
S&P Shariah Fail from an earlier screen 3 of 3 ratios pass

This Fail was decided by an earlier screen. The figures below are from the latest filing, which could not decide it on its own: non-permissible income not measured. The earlier verdict stands until a screen can decide it.

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 9.98% 33.00% Pass(23.0pp buffer)
Cash + interest-bearing securities 22.42% 49.00% Pass(26.6pp buffer)
Accounts receivable 0.00% 49.00% Pass(49.0pp buffer)
MSCI M-Series Fail from an earlier screen 3 of 3 ratios pass

This Fail was decided by an earlier screen. The figures below are from the latest filing, which could not decide it on its own: non-permissible income not measured. The earlier verdict stands until a screen can decide it.

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 9.98% 33.33% Pass(23.3pp buffer)
Cash + interest-bearing securities 22.42% 33.33% Pass(10.9pp buffer)
Accounts receivable 22.42% 49.00% Pass(26.6pp buffer)

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

Usmani (% of total assets)nonliquid assets ratio · floor 0.7pts
FTSE Shariah Global Equity Index Series (% of total assets)debt ratio 9.0pts
Usmani (% of total assets)investments ratio 46.3pts
MSCI Islamic Index (% of total assets)cash and interest ratio 46.0pts
MSCI Islamic Index (% of total assets)receivables ratio 46.0pts

The numbers the ratios are built from

Read from ELTX's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period not measured — —
Interest-bearing debtShort and long-term borrowings $9.6M 2026-09-30 LongTermDebtNoncurrent, LongTermDebtCurrent
Cash and interest-bearing securitiesCash, equivalents and marketable securities $31.4M 2026-09-30 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
Total assetsBalance sheet total $39.6M 2026-09-30 Assets
Market capDenominator for AAOIFI $41.9M live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $100.2M 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $121.7M 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $776.0K 2026-09-30 10-K text (no XBRL tag available)

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet as of 2026-09-30. Income statement as of 2026-09-30. Screened 2026-11-17.

Filing links appear after the next screen: this row was screened before filing citations were recorded.

  • Total assets$39.6M
    Assets · balance sheet as of 2026-09-30
  • Interest-bearing debt$9.6M
    LongTermDebtNoncurrent, LongTermDebtCurrent · balance sheet as of 2026-09-30
  • Cash and interest-bearing securities$31.4M
    CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · balance sheet as of 2026-09-30
  • Receivables$0
    no receivables tag reported in 3+ years (treated as $0) · balance sheet as of 2026-09-30
  • Interest income (non-permissible)$776.0K
    10-K text (no XBRL tag available) · income statement as of 2026-09-30
  • Market cap$41.9M
    Market-data quote at screen time, 2026-11-17 · not a filing figure, so no link

What changed, and when

Verdict history for ELTX. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-09-07 No change recorded No verdict change for ELTX has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.

Tracked since 2026-09-07.

What would change the status

The headline verdict is the majority of the decided ratio standards — 0 pass and 7 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30; market cap as stored on 2026-11-17.

No standard's deciding ratio sits within 3 points of its line.

The ratios that move with the share price

AAOIFI's debt ratio is $14.0M debt (operating leases included, as the screen counts it) over a market cap of $41.9M (as of 2026-11-17), 33.4% against a 30% line.

It would pass if the market cap rose above $46.6M (+11%), about $1.65 a share against $1.48 implied by the screen's own figures.

AAOIFI would then fail.

At the screen's market cap, it would take $1.4M less debt to clear the line.

AAOIFI would then fail.

AAOIFI's investments ratio is $31.4M cash and interest-bearing investments over a market cap of $41.9M (as of 2026-11-17), 75.0% against a 30% line.

It would pass if the market cap rose above $104.7M (+150%), about $3.70 a share against $1.48 implied by the screen's own figures.

AAOIFI would then be unverified.

At the screen's market cap, it would take $18.8M less cash and interest-bearing investments to clear the line.

AAOIFI would then fail.

Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.

Shariah-compliant alternatives

Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
VRTXVertex Pharmaceuticals, Inc. $121.1B $534.20-0.67%
REGNRegeneron Pharmaceuticals, Inc. $85.3B —
ARGXArgen X SE - ADR $64.3B —
ONCBeOne Medicines Ltd. American Depositary Shares $40.4B —
ALNYAlnylam Pharmaceuticals Inc $31.6B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Funds that hold ELTX

3 of the 246 funds whose filed holdings we currently hold own ELTX shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns ELTX.

You may already own it

Widely held U.S. index funds. If you own one, you own ELTX through it. None of them is a Shariah fund; the last column is our look-through of each.

FundELTX in fundFund compliant by weight
VTI VANGUARD TOTAL STOCK MARKET INDEX FUND 0.00% 54%
Other funds
FundELTX in fundFund compliant by weight
FCFMX Fidelity Series Total Market Index Fund 0.00% 51%
FSKAX Fidelity Total Market Index Fund 0.00% 51%

Sorted by ELTX’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names ELTX once, so a bond is not counted as the shares. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.

Tracked investors holding ELTX
InvestorFirmPositionWeightAs of
Ken Griffin Citadel Advisors $1M 0.0% 2026-09-30
Peter Brown Renaissance Technologies $0M 0.0% 2026-09-30
Israel Englander Millennium Management $0M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

14.8511.498.134.761.402025-11-182026-05-202026-11-17

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
1.30
S2
1.37
S1
1.42
PIVOT
1.49
R1
1.54
R2
1.61
R3
1.66

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
1.69 – 2.41
±17.65% from 2.05, made 2026-09-13 · resolves 2026-09-20
STRONG SELL
from 19 indicators
74.1% of our last 15548 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 50.3% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsSTRONG SELL
1 buy · 3 neutral · 3 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)37.40NEUTRAL
Stochastic %K (14)28.12NEUTRAL
CCI (20)-115.75BUY
Williams %R (14)-71.88NEUTRAL
MACD (12,26,9)-0.00SELL
ROC (10)-5.92SELL
Momentum (10)-0.09SELL
EMA (10)1.54SELL
SMA (10)1.53SELL
EMA (20)1.61SELL
SMA (20)1.64SELL
EMA (30)1.69SELL
SMA (30)1.67SELL
EMA (50)1.98SELL
SMA (50)1.77SELL
EMA (100)3.09SELL
SMA (100)2.43SELL
EMA (200)5.52SELL
SMA (200)6.39SELL

About ELTX

Healthcare · Biotechnology

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.

elicio.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

No real edge — avoid

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BEARISH 43
⏰ 4H RANGING 31
🕐 1H BEARISH 98
⏱ 15-Min RANGING 130
⏲ 5-Min BEARISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-5.6%
Rate of change (10d)
4.4×
Volume vs its 20-day average
-0.08
MACD (no fresh cross)
$1.40
Volume POC (today)
$1.37 – $1.44
Value area

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-10 · Asset managers net 914130 (-14454)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.